UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

HIV medicine, 2017-01, Vol.18 (1), p.56-63

2017

Volltextzugriff (PDF)

Reply to Letter ‘Morning dosing for dolutegravir‐related insomnia and sleep disorders’ by Capetti et al

HIV medicine, 2018-05, Vol.19 (5), p.e60-e61

2018

Volltextzugriff (PDF)

745 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBSAG LOSS OR SERO-CONVERSION IN HBEAG NEGATIVE CHB PATIENTS: EXPERIENCE FROM FOUR REFERRAL CENTERS IN GERMANY

Journal of hepatology, 2011-03, Vol.54, p.S299-S300

2011

Volltextzugriff (PDF)

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients

AIDS (London), 2012-02, Vol.26 (4), p.457-464

2012

Volltextzugriff (PDF)

Infektionskrankheiten der Haut: Grundlagen, Diagnostik und Therapiekonzepte für Dermatologen, Internisten und Pädiater

3. vollständig überarbeitete Auflage.

Volltextzugriff (PDF)

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome

Critical care (London, England), 1997, Vol.1 (Suppl 1), p.P024-P024

1997

Volltextzugriff (PDF)

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome: 90

Shock (Augusta, Ga.), 1997-03, Vol.7 (Supplement), p.23

1997

Volltextzugriff (PDF)

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome.: 90

Shock (Augusta, Ga.), 1997-03, Vol.7 Suppl, p.23-23

1997

Volltextzugriff (PDF)

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Journal of antimicrobial chemotherapy, 2021-09, Vol.76 (9), p.2380-2393

2021

Volltextzugriff (PDF)

Dolutegravir + Lamivudin ile Gercek Dunya HIV-1 Sonuclari: Alman URBAN Kohortu

Mediterranean journal of infection, microbes & antimicrobials, 2024-01, Vol.13, p.102

2024

Volltextzugriff (PDF)

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(11)
Bücher
(1)

Sprache

Englisch
(11)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Reply to Letter ‘Morning dosing for dolutegravir‐related insomnia and sleep disorders’ by Capetti et al

745 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBSAG LOSS OR SERO-CONVERSION IN HBEAG NEGATIVE CHB PATIENTS: EXPERIENCE FROM FOUR REFERRAL CENTERS IN GERMANY

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients

Infektionskrankheiten der Haut: Grundlagen, Diagnostik und Therapiekonzepte für Dermatologen, Internisten und Pädiater

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome: 90

Induction of endotoxin (ET) tolerance by atoxic endotoxin - a new prophylactic concept to the septic syndrome.: 90

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Dolutegravir + Lamivudin ile Gercek Dunya HIV-1 Sonuclari: Alman URBAN Kohortu

Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial

Suchergebnisse filtern